3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
4
Glioma
3
Multiple Myeloma
2
Melanoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Ganglioneuroma
1
Ganglioglioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
tisagenlecleucel
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
zanubrutinib
1
selinexor
1
revumenib
1
niraparib
1
nilotinib
1
ivosidenib
1
imetelstat
1
ibrutinib
1
entrectinib
1
dostarlimab
1
brexucabtagene autoleucel
1
avapritinib
1
asciminib
1
Standard of Care
1
Paclitaxel
1
Imatinib Mesylate
1
GRN163L peptide
1
Drug Therapy
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has announcements
×
Recurrence
×
dabrafenib
×
Clear all
No trials found.